Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease

Part of paid clinical trials in Durham, North Carolina.

Sponsor
Duke University
Study ID
NCT05237388
Phase
PHASE2
Status
Completed

Conditions

  • Chronic Kidney Diseases

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Baricitinib — DRUG
    One pill daily
  • Placebo — DRUG
    Baricitinib placebo pill

Study Details

The purpose of this study is to determine if the drug, baricitinib, is safe and effective in reducing high levels of albumin in the urine (albuminuria) in African American/Blacks with APOL1- associated focal segmental glomerulosclerosis (FSGS) and non-diabetic APOL1-associated chronic kidney disease due to hypertension (HTN-CKD).

Key Dates

Start date
Apr 20, 2023
Status verified
Apr 2026
Primary completion
Apr 3, 2026
Completion
Apr 3, 2026

Study Design

Enrollment
8 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Baricitinib
    Participants will take one pill of Baricitinib daily with their regular medications.
  • Placebo Comparator: Placebo
    Participants will take a Baricitinib placebo pill matching Baricitinib daily with their regular medications.

Primary Outcome Measure

Percent change in albuminuria (UACR) [ Time Frame: Baseline, monthly for 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Duke Research at Pickett RoadDurhamNorth Carolina27705-

Find similar trials in Durham, NC

By research site
Duke Research at Pickett Road· Durham, NC

Related Studies